Regeneron posted Q2 2026 adjusted earnings of $14.29 per share, topping the $10.53 consensus, while revenue climbed 17% to $4.3 billion. The beat reflects strong Dupixent growth and a $3 billion investment that represents roughly 4% of its $73.7 billion market value, bolstering investor confidence.

Key Highlights

  • Price movement modest; Dupixent sales $6.0 billion; next catalyst: FDA priority review for cemdisiran Nov 2026
  • Q2 revenue $4.291 billion, up 17% YoY; GAAP EPS $12.23, non‑GAAP EPS $14.29
  • EYLEA HD U.S. sales $596 million (+52% YoY); Libtayo sales $489 million (+30% YoY)

Regeneron Pharmaceuticals (NASDAQ: REGN) posted a strong second‑quarter performance, delivering adjusted earnings of $14.29 per diluted share and total revenue of $4.291 billion, reflecting a 17% year‑over‑year increase. The earnings uplift was driven primarily by strong sales of Dupixent.

By the Numbers

GAAP earnings per share were $12.23, while non‑GAAP earnings per share reached $14.29. The company reported per‑share reductions related to IPR&D expenses of $1.02 and $0.99, respectively.

Segment Detail

Dupixent’s global net sales rose 38% to $6.0 billion, benefitting from recent regulatory approvals in the United States and Europe. EYLEA HD net product sales in the United States increased 52% to $596 million, following an FDA decision to extend dosing intervals. Libtayo’s global net sales grew 30% to $489 million, reinforcing the oncology portfolio.

Guidance

Ongoing regulatory review of cemdisiran continues, with the FDA targeting a priority‑review action date in November 2026 and the European Commission expected to render a decision in the latter half of 2027.

Market Reaction

Following the release, Regeneron’s share price showed a modest increase, outperforming broader sector peers that experienced declines. The market response highlighted investor confidence in the earnings beat and the forthcoming regulatory milestone for cemdisiran, which may add further upside potential.

Peers Moving on This News

  • AbbVie Inc (ABBV) down 2.5%
  • Amgen Inc (AMGN) down 1.6%
  • Gilead Sciences, Inc (GILD) down 2.5%

Analysis based on company disclosures and public reporting; figures verified against the source and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.